Please assess the completion status of the following clinical trial:

Trial Title: A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients in whom pelvic lymph node dissection can be performed;~* Any male and/or female, who is ≥18 years of age;~* Pathological diagnosis of urothelial carcinoma of the bladder;~* Localized muscle-invasive disease defined as clinical stage T2-4aN0M0 tumors;~* Did not receive neoadjuvant therapy;~* No radiographic evidence of metastatic disease on CT scans of the abdomen and pelvis, chest x-ray, or bone scan;~* Informed consent before study participation~Exclusion Criteria:~* Prior systemic chemotherapy;~* Prior radiation therapy;~* A history of another ongoing malignancy within the past 5 years other than basal cell carcinoma of the skin

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Blood sample (Type: None): the blood sample only collected prior to surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).